Current
Neuro-Oncology


Volume 22 Number 3
March 2020


Home > Publications > Current Neuro-Oncology > Volume 22, Year 2020 > Number 3, March


CONTENTS


CENTRAL NERVOUS SYSTEM TUMORS




GLIOMAS


HIGH-GRADE GLIOMAS


GLIOMATOSIS CEREBRI




DIFFUSE ASTROCYTIC AND OLIGODENDROGLIAL TUMORS


DIFFUSE ASTROCYTOMA


GLIOBLASTOMA


GLIOSARCOMA


DIFFUSE MIDLINE GLIOMA




OTHER ASTROCYTIC TUMORS


PLEOMORPHIC XANTHOASTROCYTOMA




EMBRYONAL TUMORS


MEDULLOBLASTOMA




LYMPHOMAS





CENTRAL NERVOUS SYSTEM TUMORS


Meazza C, Schiavello E, Biassoni V, Podda M, Barteselli C, Barretta F, Gattuso G, Terenziani M, Ferrari A, Spreafico F, Luksch R, Casanova M, Chiaravalli S, Puma N, Bergamaschi L, Massimino M.
Cancer treatment in disabled children.
Eur J Pediatr. 2020 Mar 5. Doi: 10.1007/s00431-020-03607-6. Epub ahead of print. _




Pasqual E, Castaño-Vinyals G, Thierry-Chef I, Kojimahara N, Sim MR, Kundi M, Krewski D, Momoli F, Lacour B, Remen T, Radon K, Weinmann T, Petridou E, Moschovi M, Dikshit R, Sadetski S, Maule M, Farinotti M, Ha M, 't Mannetje A, Alguacil J, Aragonés N, Vermeulen R, Kromhout H, Cardis E.
Exposure to Medical Radiation during Fetal Life, Childhood and Adolescence and Risk of Brain Tumor in Young Age: Results from The MOBI-Kids Case-Control Study.
Neuroepidemiology. 2020 Mar 20:1-13. Doi: 10.1159/000506131. Epub ahead of print. _



GLIOMAS


Federici L, Capelle L, Annereau M, Bielle F, Willekens C, Dehais C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Idbaih A, Lemare F, de Botton S, Sanson M, Touat M.
5-Azacitidine in Patients with IDH1/2-mutant Recurrent Glioma.
Neuro Oncol. 2020 Mar 26:noaa074. Doi: 10.1093/neuonc/noaa074. Epub ahead of print. _




Han Y, Wang W, Yang Y, Sun YZ, Xiao G, Tian Q, Zhang J, Cui GB, Yan LF.
Amide Proton Transfer Imaging in Predicting Isocitrate Dehydrogenase 1 Mutation Status of Grade II/III Gliomas Based on Support Vector Machine.
Front Neurosci. 2020 Feb 21;14:144. Doi: 10.3389/fnins.2020.00144. _




Sharifi G, Pajavand AM, Nateghinia S, Meybodi TE, Hasooni H.
Glioma Migration Through the Corpus Callosum and the Brainstem Detected by Diffusion and Magnetic Resonance Imaging: Initial Findings.
Front Hum Neurosci. 2020 Feb 25;13:472. Doi: 10.3389/fnhum.2019.00472. _




Wu X, Li Y, Glastonbury CM, Cha S.
Involvement of the Olfactory Apparatus by Gliomas.
AJNR Am J Neuroradiol. 2020 Mar 12. Doi: 10.3174/ajnr.A6471. Epub ahead of print. _




Yamashiro K, Nakao K, Ohba S, Hirose Y.
Human Glioma Cells Acquire Temozolomide Resistance After Repeated Drug Exposure Via DNA Mismatch Repair Dysfunction.
Anticancer Res. 2020 Mar;40(3):1315-1323. Doi: 10.21873/anticanres.14073.. _




Zhang Z, Xin J.
Dietary fresh fish and processed fish intake and the risk of glioma: A meta-analysis of observational studies.
Cell Mol Biol (Noisy-le-grand). 2019 Dec 31; 65(8):48-53.. _



HIGH-GRADE GLIOMAS



Chan J, Jayamanne D, Wheeler H, Khasraw M, Wong M, Kastelan M, Guo L, Back M.
The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma.
Clin Transl Radiat Oncol. 2020 Mar 9;22:33-39. Doi: 10.1016/j.ctro.2020.03.005. _




Dutoit V, Philippin G, Widmer V, Marinari E, Vuilleumier A, Migliorini D, Schaller K, Dietrich PY.
Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients.
Front Oncol. 2020 Feb 14;10:89. Doi: 10.3389/fonc.2020.00089. _




Khurana R, Rath S, Singh HB, Rastogi M, Nanda SS, Chauhan A, Kaif M, Hussain N.
Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation.
Asian Pac J Cancer Prev. 2020 Mar 1;21(3):755-760. Doi: 10.31557/APJCP.2020.21.3.755. _




Kong L, Wu J, Gao J, Qiu X, Yang J, Hu J, Hu W, Mao Y, Lu JJ.
Particle radiation therapy in the management of malignant glioma: Early experience at the Shanghai Proton and Heavy Ion Center.
Cancer. 2020 Mar 13. Doi: 10.1002/cncr.32828. Epub ahead of print. _




Nunna RS, Khalid S, Ryoo JS, Mehta AI.
Adult primary high-grade spinal glioma: a nationwide analysis of current trends in treatment and outcomes.
J Neurooncol. 2020 Mar 17. Doi: 10.1007/s11060-020-03458-z. Epub ahead of print. _




Rudnick JD, Sarmiento JM, Uy B, Nuno M, Wheeler CJ, Mazer MJ, Wang H, Hu JL, Chu RM, Phuphanich S, Black KL, Yu JS.
A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
J Clin Neurosci. 2020 Mar 10:S0967-5868(19)31766-7. Doi: 10.1016/j.jocn.2020.03.006. Epub ahead of print. _




Wick A, Desjardins A, Suarez C, Forsyth P, Gueorguieva I, Burkholder T, Cleverly AL, Estrem ST, Wang S, Lahn MM, Guba SC, Capper D, Rodon J.
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Invest New Drugs. 2020 Mar 5. Doi: 10.1007/s10637-020-00910-9. Epub ahead of print. _




Yamamoto J, Kitagawa T, Miyaoka R, Suzuki K, Takamatsu S, Saito T, Nakano Y.
5-Aminolevulinic Acid: Pitfalls of Fluorescence-guided Resection for Malignant Gliomas and Application for Malignant Glioma Therapy.
J UOEH. 2020;42(1):27-34. Doi: 10.7888/juoeh.42.27. Released: March 25, 2020. _




Zhao YY, Wan QS, Hao Z, Zhu HX, Xing ZL, Li MH.
Clinical nomogram for predicting the survival of patients with cerebral anaplastic gliomas.
Medicine (Baltimore). 2020 Mar;99(10):e19416. Doi: 10.1097/MD.0000000000019416. _



GLIOMATOSIS CEREBRI



Anghileri E, Schettino C, Pollo B, Farinotti M, Silvani A, Paterra R, Patanè M, DiMeco F, Bruzzone MG, Eoli M, Cuccarini V.
Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series.
Neurol Sci. 2020 Feb 29. Doi: 10.1007/s10072-020-04288-7. Epub ahead of print. _



DIFFUSE ASTROCYTIC AND OLIGODENDROGLIAL TUMORS



DIFFUSE ASTROCYTOMA



Tunthanathip T, Ratanalert S, Sae-Heng S, Oearsakul T, Sakaruncchai I, Kaewborisutsakul A, Chotsampancharoen T, Intusoma U, Kitkhuandee A, Vaniyapong T.
Prognostic Factors and Nomogram Predicting Survival in Diffuse Astrocytoma.
J Neurosci Rural Pract. 2020 Jan;11(1):135-143. Doi: 10.1055/s-0039-3403446. Epub 2020 Mar 3. _



GLIOBLASTOMA



Akbari H, Rathore S, Bakas S, Nasrallah MP, Shukla G, Mamourian E, Rozycki M, Bagley SJ, Rudie JD, Flanders AE, Dicker AP, Desai AS, O'Rourke DM, Brem S, Lustig R, Mohan S, Wolf RL, Bilello M, Martinez-Lage M, Davatzikos C.
Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma.
Cancer. 2020 Mar 4. Doi: 10.1002/cncr.32790. Epub ahead of print. _




Brem S, Henderson F.
Commentary: 5-Aminolevulinic Acid and Contrast-Enhanced Ultrasound: The Combination of the 2 Techniques to Optimize the Extent of Resection in Glioblastoma Surgery.
Neurosurgery. 2020 Mar 18:nyaa061. Doi: 10.1093/neuros/nyaa061. Epub ahead of print. _




Brown NF, Ng SM, Brooks C, Coutts T, Holmes J, Roberts C, Elhussein L, Hoskin P, Maughan T, Blagden S, Mulholland P.
A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Gliotrial protocol.
BMC Cancer. 2020 Mar 12;20(1):198. Doi: 10.1186/s12885-020-6624-y. _




Buszek SM, Al Feghali KA, Elhalawani H, Chevli N, Allen PK, Chung C.
Optimal Timing of Radiotherapy Following Gross Total or Subtotal Resection of Glioblastoma: A Real-World Assessment using the National Cancer Database.
Sci Rep. 2020 Mar 18;10(1):4926. Doi: 10.1038/s41598-020-61701-z. _




Della Pepa GM, Ius T, La Rocca G, Gaudino S, Isola M, Pignotti F, Rapisarda A, Mazzucchi E, Giordano C, Dragonetti V, Chiesa S, Balducci M, Gessi M, Skrap M, Olivi A, Marchese E, Sabatino G.
5-Aminolevulinic Acid and Contrast-Enhanced Ultrasound: The Combination of the Two Techniques to Optimize the Extent of Resection in Glioblastoma Surgery.
Neurosurgery. 2020 Mar 18:nyaa037. Doi: 10.1093/neuros/nyaa037. Epub ahead of print. _




El Husseini K, Marguet F, Lamy A, Magne N, Fontanilles M.
Major response to temozolomide as first-line treatment for newly-diagnosed DDR2-mutated glioblastoma: A case report.
Rev Neurol (Paris). 2020 Mar 2:S0035-3787(20)30396-9. Doi: 10.1016/j.neurol.2019.09.007. _




Finneran M, Marotta DA, Altenburger D, Nardone E.
Long-term Survival in a Patient with Butterfly Glioblastoma: A Case Report.
Cureus. 2020 Feb 7;12(2):e6914. Doi: 10.7759/cureus.6914. _




Henderson F Jr, Brem S, O'Rourke DM, Nasrallah M, Buch VP, Young AJ, Doot RK, Pantel A, Desai A, Bagley SJ, Nabavizadeh SA.
18F-Fluciclovine PET to distinguish treatment-related effects from disease progression in recurrent glioblastoma: PET fusion with MRI guides neurosurgical sampling.
Neurooncol Pract. 2020 Mar;7(2):152-157. Doi: 10.1093/nop/npz068. Epub 2019 Dec 8. _




Jeanmougin M, Håvik AB, Cekaite L, Brandal P, Sveen A, Meling TR, Ågesen TH, Scheie D, Heim S, Lothe RA, Lind GE.
Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
Mol Oncol. 2020 Mar 14. Doi: 10.1002/1878-0261.12668. Epub ahead of print. _



*

Jin Y, Randall JW, Elhalawani H, Feghali KAA, Elliott AM, Anderson BM, Lacerda L, Tran BL, Mohamed AS, Brock KK, Fuller CD, Chung C.
Detection of Glioblastoma Subclinical Recurrence Using Serial Diffusion Tensor Imaging.
Cancers (Basel). 2020 Feb 29;12(3):E568. Doi: 10.3390/cancers12030568. _




Lee EQ, Zhang P, Wen PY, Gerstner ER, Reardon DA, Aldape KD, deGroot JF, Pan E, Raizer JJ, Kim LJ, Chmura SJ, Robins HI, Connelly JM, Battiste JD, Villano JL, Wagle N, Merrell RT, Wendland MM, Mehta MP.
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
Cancer. 2020 Mar 10. Doi: 10.1002/cncr.32811. Epub ahead of print. _




Marcus AP, Marcus HJ, Camp SJ, Nandi D, Kitchen N, Thorne L.
Improved Prediction of Surgical Resectability in Patients with Glioblastoma using an Artificial Neural Network.
Sci Rep. 2020 Mar 20;10(1):5143. Doi: 10.1038/s41598-020-62160-2. _




Massey SC, White H, Whitmire P, Doyle T, Johnston SK, Singleton KW, Jackson PR, Hawkins-Daarud A, Bendok BR, Porter AB, Vora S, Sarkaria JN, Hu LS, Mrugala MM, Swanson KR.
Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma.
PLoS One. 2020 Mar 27;15(3):e0230492. Doi: 10.1371/journal.pone.0230492. _




Metz MC, Molina-Romero M, Lipkova J, Gempt J, Liesche-Starnecker F, Eichinger P, Grundl L, Menze B, Combs SE, Zimmer C, Wiestler B.
Predicting Glioblastoma Recurrence from Preoperative MR Scans Using Fractional-Anisotropy Maps with Free-Water Suppression.
Cancers (Basel). 2020 Mar 19;12(3):E728. Doi: 10.3390/cancers12030728. _




Park JE, Kim HS, Park SY, Jung SC, Kim JH, Heo HY.
Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Radiology. 2020 Mar 10:191376. Doi: 10.1148/radiol.2020191376. Epub ahead of print. _




Park JE, Kim HS, Jo Y, Yoo RE, Choi SH, Nam SJ, Kim JH.
Radiomics prognostication model in glioblastoma using diffusion- and perfusion-weighted MRI.
Sci Rep. 2020 Mar 6;10(1):4250. Doi: 10.1038/s41598-020-61178-w. _




Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR.
A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma.
Neuro Oncol. 2020 Mar 13:noaa062. Doi: 10.1093/neuonc/noaa062. Epub ahead of print. _




Ranjan T, Howard CM, Yu A, Xu L, Aziz K, Jho D, Leonardo J, Hameed MA, Karlovits SM, Wegner RE, Fuhrer R, Lirette ST, Denning KL, Valluri J, Claudio PP.
Cancer Stem Cell Chemotherapeutics Assay for Prospective Treatment of Recurrent Glioblastoma and Progressive Anaplastic Glioma: A Single-Institution Case Series.
Transl Oncol. 2020 Mar 17;13(4):100755. Doi: 10.1016/j.tranon.2020.100755. Epub ahead of print. _




Scartoni D, Amelio D, Palumbo P, Giacomelli I, Amichetti M.
Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma.
J Cancer Res Clin Oncol. 2020 Mar 21. Doi: 10.1007/s00432-020-03187-w. Epub ahead of print. _




Song J, Kadaba P, Kravitz A, Hormigo A, Friedman J, Belani P, Hadjipanayis C, Ellingson BM, Nael K.
Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.
Neuro Oncol. 2020 Mar 20:noaa066. Doi: 10.1093/neuonc/noaa066. Epub ahead of print. _




Urup T, Gillberg L, Kaastrup K, Lü MJS, Michaelsen SR, Andrée Larsen V, Christensen IJ, Broholm H, Lassen U, Grønbaek K, Poulsen HS.
Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma.
Mol Oncol. 2020 Mar 5. Doi: 10.1002/1878-0261.12660. Epub ahead of print. _




Wańkowicz P, Rogińska D, Machaliński B, Nowacki P.
Expression of markers of neural stem and progenitor cells in glioblastoma multiforme in relation to tumor recurrence and overall survival.
Arch Med Sci. 2020 Feb 4;16(2):481-483. Doi: 10.5114/aoms.2020.92857. _




White-Gilbertson S, Lu P, Jones CM, Chiodini S, Hurley D, Das A, Delaney JR, Norris JS, Voelkel-Johnson C.
Tamoxifen is a candidate first-in-class inhibitor of acid ceramidase that reduces amitotic division in polyploid giant cancer cells-Unrecognized players in tumorigenesis.
Cancer Med. 2020 Mar 5. Doi: 10.1002/cam4.2960. Epub ahead of print. _



GLIOSARCOMA



Jin MC, Liu EK, Shi S, Gibbs IC, Thomas R, Recht L, Soltys SG, Pollom EL, Chang SD, Hayden Gephart M, Nagpal S, Li G.
Evaluating Surgical Resection Extent and Adjuvant Therapy in the Management of Gliosarcoma.
Front Oncol. 2020 Mar 11;10:337. Doi: 10.3389/fonc.2020.00337. _




Zhang Y, Ma JP, Weng JC, Wang L, Wu Z, Li D, Zhang JT.
The clinical, radiological, and immunohistochemical characteristics and outcomes of primary intracranial gliosarcoma: a retrospective single-centre study.
Neurosurg Rev. 2020 Mar 18. Doi: 10.1007/s10143-020-01285-4. Epub ahead of print. _



DIFFUSE MIDLINE GLIOMA



Fortin J, Tian R, Zarrabi I, Hill G, Williams E, Sanchez-Duffhues G, Thorikay M, Ramachandran P, Siddaway R, Wong JF, Wu A, Apuzzo LN, Haight J, You-Ten A, Snow BE, Wakeham A, Goldhamer DJ, Schramek D, Bullock AN, Dijke PT, Hawkins C, Mak TW.
Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas.
Cancer Cell. 2020 Mar 16;37(3):308-323.e12. Doi: 10.1016/j.ccell.2020.02.002. Epub 2020 Mar 5. _




Giussani C, Guida L, Biassoni V, Schiavello E, Carrabba G, Trezza A, Sganzerla E, Massimino M.
Retrospective analysis of the clinical and radiological features of 94 consecutive DIPGs patients to investigate the factors determining the development of hydrocephalus and its impact on clinical status and survival.
Childs Nerv Syst. 2020 Mar 28. Doi: 10.1007/s00381-020-04589-4. Epub ahead of print. _




Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, Bartels U, Albrecht S, Schwartzentruber J, Letourneau L, Bourgey M, Bourque G, Montpetit A, Bourret G, Lepage P, Fleming A, Lichter P, Kool M, von Deimling A, Sturm D, Korshunov A, Faury D, Jones DT, Majewski J, Pfister SM, Jabado N, Hawkins C.
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
Acta Neuropathol. 2012 Sep;124(3):439-47. Doi: 10.1007/s00401-012-0998-0. Epub 2012 Jun 3. _




Luo Y, Zeng L, Xie XQ, Wang F, Liu YZ, Kang JB, Li XF, Wu DB, Qu BL.
H3K27M mutant diffuse midline glioma: a case report.
Eur Rev Med Pharmacol Sci. 2020 Mar;24(5):2579-2584. Doi: 10.26355/eurrev_202003_20527. _




Meel MH, de Gooijer MC, Metselaar DS, Sewing ACP, Zwaan K, Waranecki P, Breur M, Buil LCM, Lagerweij T, Wedekind LE, Twisk JWR, Koster J, Hashizume R, Raabe EH, Montero-Carcaboso A, Bugiani M, Phoenix TN, van Tellingen O, van Vuurden DG, Kaspers GJL, Hulleman E.
Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma.
Clin Cancer Res. 2020 Mar 12:clincanres.3538.2019. Doi: 10.1158/1078-0432.CCR-19-3538. Epub ahead of print. _




Niu X, Wang T, Zhou X, Yang Y, Wang X, Zhang H, Chen N, Yue Q, Wang F, Zhang Y, Liu Y, Mao Q.
Surgical treatment and survival outcome of patients with adult thalamic glioma: a single institution experience of 8 years.
J Neurooncol. 2020 Apr;147(2):377-386. Doi: 10.1007/s11060-020-03430-x. Epub 2020 Mar 10. _




Pratt D, Quezado M, Abdullaev Z, Hawes D, Yang F, Garton HJL, Judkins AR, Mody R, Chinnaiyan A, Aldape K, Koschmann C, Venneti S.
Diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma.
Acta Neuropathol Commun. 2020 Mar 20;8(1):37. Doi: 10.1186/s40478-020-00905-w. _




Szychot E, Youssef A, Ganeshan B, Endozo R, Hyare H, Gains J, Mankad K, Shankar A.
Predicting Outcome In Childhood Diffuse Midline Gliomas Using Magnetic Resonance Imaging Based Texture Analysis.
J Neuroradiol. 2020 Mar 14:S0150-9861(20)30131-0. Doi: 10.1016/j.neurad.2020.02.005. Epub ahead of print. _



OTHER ASTROCYTIC TUMORS



PLEOMORPHIC XANTHOASTROCYTOMA



Luna LP, da Ponte IM, Oliveira IB, Ramos F Jr, Gerson G.
Pleomorphic xanthoastrocytoma in the posterior fossa: a case report with advanced neuroimaging findings.
Clin Imaging. 2020 Feb 25;63:30-34. Doi: 10.1016/j.clinimag.2020.02.010. Epub ahead of print. _



EMBRYONAL TUMORS



MEDULLOBLASTOMA



Eberhart C.
Astrocytes - New Stars In The Medulloblastoma Firmament.
Neuro Oncol. 2020 Mar 11:noaa057. Doi: 10.1093/neuonc/noaa057. Epub ahead of print. _
Referring to: Liu H et al., Necroptotic astrocytes contribute to maintaining stemness of disseminated medulloblastoma through CCL2 secretion. Neuro Oncol. 2019 Nov 15:noz214. Doi: 10.1093/neuonc/noz214. Epub ahead of print. _




Hidalgo Santos AD, de Mingo Alemany MDC, Moreno Macián F, León Cariñena S, Collado Ballesteros E, Cañete Nieto A.
Endocrinological late effects of oncologic treatment on survivors of medulloblastoma.
Rev Chil Pediatr. 2019 Dec;90(6):598-605. Doi: 10.32641/rchped.v90i6.994. _




Khatua S, Cooper LJN, Sandberg DI, Ketonen L, Johnson JM, Rytting ME, Liu DD, Meador H, Trikha P, Nakkula RJ, Behbehani GK, Ragoonanan D, Gupta S, Kotrotsou A, Idris T, Shpall EJ, Rezvani K, Colen R, Zaky W, Lee DA, Gopalakrishnan V.
Phase I study of intraventricular infusions of autologous ex-vivo-expanded NK cells in children with recurrent medulloblastoma and ependymoma.
Neuro Oncol. 2020 Mar 10:noaa047. Doi: 10.1093/neuonc/noaa047. Epub ahead of print. _




Liu H, Sun Y, O'Brien JA, Franco-Barraza J, Qi X, Yuan H, Jin W, Zhang J, Gu C, Zhao Z, Yu C, Feng S, Yu X.
Necroptotic astrocytes contribute to maintaining stemness of disseminated medulloblastoma through CCL2 secretion.
Neuro Oncol. 2019 Nov 15:noz214. Doi: 10.1093/neuonc/noz214. Epub ahead of print. _




Peng J, Zhou H, Tang O, Chang K, Wang P, Zeng X, Shen Q, Wu J, Xiao Y, Patel SH, Hu C, Jin K, Xiao B, Boxerman J, Gao X, Wen PY, Bai HX, Huang RY, Yang L.
Evaluation of RAPNO criteria in medulloblastoma and other leptomeningeal seeding tumors using MRI and clinical data.
Neuro Oncol. 2020 Mar 26:noaa072. Doi: 10.1093/neuonc/noaa072. Epub ahead of print. _



LYMPHOMAS


Perez-Roman RJ, Hubbard ZS, Brusko GD, Starke RM.
A case of primary central nervous system lymphoma presenting as a shunt complication.
Br J Neurosurg. 2020 Mar 12:1-4. Doi: 10.1080/02688697.2020.1735300. Epub ahead of print. _



bottom